Your browser doesn't support javascript.
loading
Mendelian randomisation identifies alternative splicing of the FAS death receptor as a mediator of severe COVID-19.
Klaric, Lucija; Gisby, Jack S; Papadaki, Artemis; Muckian, Marisa D; Macdonald-Dunlop, Erin; Zhao, Jing Hua; Tokolyi, Alex; Persyn, Elodie; Pairo-Castineira, Erola; Morris, Andrew P; Kalnapenkis, Anette; Richmond, Anne; Landini, Arianna; Hedman, Åsa K; Prins, Bram; Zanetti, Daniela; Wheeler, Eleanor; Kooperberg, Charles; Yao, Chen; Petrie, John R; Fu, Jingyuan; Folkersen, Lasse; Walker, Mark; Magnusson, Martin; Eriksson, Niclas; Mattsson-Carlgren, Niklas; Timmers, Paul R H J; Hwang, Shih-Jen; Enroth, Stefan; Gustafsson, Stefan; Vosa, Urmo; Chen, Yan; Siegbahn, Agneta; Reiner, Alexander; Johansson, Åsa; Thorand, Barbara; Gigante, Bruna; Hayward, Caroline; Herder, Christian; Gieger, Christian; Langenberg, Claudia; Levy, Daniel; Zhernakova, Daria V; Smith, J Gustav; Campbell, Harry; Sundstrom, Johan; Danesh, John; Michaëlsson, Karl; Suhre, Karsten; Lind, Lars.
Affiliation
  • Klaric L; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, UK.
  • Gisby JS; Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK.
  • Papadaki A; Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK.
  • Muckian MD; Centre for Global Health Research, Usher Institute, University of Edinburgh, Teviot Place, Edinburgh, UK.
  • Macdonald-Dunlop E; Centre for Global Health Research, Usher Institute, University of Edinburgh, Teviot Place, Edinburgh, UK.
  • Zhao JH; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Tokolyi A; Department of Human Genetics, Wellcome Sanger Institute, Hinxton, UK.
  • Persyn E; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Pairo-Castineira E; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, UK.
  • Morris AP; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, UK.
  • Kalnapenkis A; Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK.
  • Richmond A; Institute of Genomics, University of Tartu, 51010, Estonia.
  • Landini A; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, UK.
  • Hedman ÅK; Centre for Global Health Research, Usher Institute, University of Edinburgh, Teviot Place, Edinburgh, UK.
  • Prins B; Department of Medicine, Karolinska Institute, Stockholm, Sweden.
  • Zanetti D; Pfizer Worldwide Research, Development and Medical, Sweden.
  • Wheeler E; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Kooperberg C; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
  • Yao C; MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK.
  • Petrie JR; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Fu J; Population Sciences Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
  • Folkersen L; Framingham Heart Study, Framingham, MA, USA.
  • Walker M; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
  • Magnusson M; Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Eriksson N; Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Mattsson-Carlgren N; Danish National Genome Center, Copenhagen, Denmark.
  • Timmers PRHJ; Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Hwang SJ; Department of Clinical Sciences, Lund University, Malmö, Sweden.
  • Enroth S; Wallenberg Center for Molecular Medicine, Lund University, Sweden.
  • Gustafsson S; Hypertension in Africa Research Team (HART), North West University, Potchefstroom, South Africa.
  • Vosa U; Uppsala Clinical Research Center (UCR), Uppsala University, Uppsala, Sweden.
  • Chen Y; Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.
  • Siegbahn A; Department of Neurology, Skåne University Hospital, Lund University, Lund, Sweden.
  • Reiner A; Wallenberg Center for Molecular Medicine, Lund University, Sweden.
  • Johansson Å; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, UK.
  • Thorand B; Centre for Global Health Research, Usher Institute, University of Edinburgh, Teviot Place, Edinburgh, UK.
  • Gigante B; Population Sciences Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
  • Hayward C; Framingham Heart Study, Framingham, MA, USA.
  • Herder C; Department of Immunology, Genetics and Pathology, Uppsala University, Sweden.
  • Gieger C; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Langenberg C; Institute of Genomics, University of Tartu, 51010, Estonia.
  • Levy D; Department of Medicine, Karolinska Institute, Stockholm, Sweden.
  • Zhernakova DV; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Smith JG; Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
  • Campbell H; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Sundstrom J; Department of Immunology, Genetics and Pathology, Uppsala University, Sweden.
  • Danesh J; Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, München-Neuherberg, Germany.
  • Michaëlsson K; German Center for Diabetes Research (DZD), München-Neuherberg, Germany.
  • Suhre K; Division of Cardiovascular Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Lind L; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, UK.
medRxiv ; 2021 Apr 07.
Article de En | MEDLINE | ID: mdl-33851187
Severe COVID-19 is characterised by immunopathology and epithelial injury. Proteomic studies have identified circulating proteins that are biomarkers of severe COVID-19, but cannot distinguish correlation from causation. To address this, we performed Mendelian randomisation (MR) to identify proteins that mediate severe COVID-19. Using protein quantitative trait loci (pQTL) data from the SCALLOP consortium, involving meta-analysis of up to 26,494 individuals, and COVID-19 genome-wide association data from the Host Genetics Initiative, we performed MR for 157 COVID-19 severity protein biomarkers. We identified significant MR results for five proteins: FAS, TNFRSF10A, CCL2, EPHB4 and LGALS9. Further evaluation of these candidates using sensitivity analyses and colocalization testing provided strong evidence to implicate the apoptosis-associated cytokine receptor FAS as a causal mediator of severe COVID-19. This effect was specific to severe disease. Using RNA-seq data from 4,778 individuals, we demonstrate that the pQTL at the FAS locus results from genetically influenced alternate splicing causing skipping of exon 6. We show that the risk allele for very severe COVID-19 increases the proportion of transcripts lacking exon 6, and thereby increases soluble FAS. Soluble FAS acts as a decoy receptor for FAS-ligand, inhibiting apoptosis induced through membrane-bound FAS. In summary, we demonstrate a novel genetic mechanism that contributes to risk of severe of COVID-19, highlighting a pathway that may be a promising therapeutic target.

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Clinical_trials Langue: En Journal: MedRxiv Année: 2021 Type de document: Article Pays de publication: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Clinical_trials Langue: En Journal: MedRxiv Année: 2021 Type de document: Article Pays de publication: États-Unis d'Amérique